NASDAQ:SLNO - Soleno Therapeutics Stock Price, Forecast & News

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Soleno Therapeutics's stock reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its earnings results on Wednesday, August, 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.14. View Soleno Therapeutics' Earnings History.

Soleno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Soleno Therapeutics.

3 analysts have issued twelve-month target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect Soleno Therapeutics' share price to reach $9.33 in the next year. This suggests a possible upside of 177.0% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.

Media stories about SLNO stock have trended extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a news sentiment score of -4.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Soleno Therapeutics.

Soleno Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 239,200 shares, a drop of 38.2% from the January 15th total of 387,000 shares. Based on an average daily volume of 287,900 shares, the short-interest ratio is currently 0.8 days. Approximately 0.8% of the company's stock are short sold. View Soleno Therapeutics' Current Options Chain.

Some companies that are related to Soleno Therapeutics include TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Zynex (ZYXI), Viewray (VRAY), BioLife Solutions (BLFS), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), IRIDEX (IRIX), Fc Global Realty (FCRE) and electroCore (ECOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Agile Therapeutics (AGRX), Opko Health (OPK), Molecular Templates (MTEM), VBI Vaccines (VBIV), SCYNEXIS (SCYX), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL), Tetraphase Pharmaceuticals (TTPH), AcelRx Pharmaceuticals (ACRX) and Aduro BioTech (ADRO).

Soleno Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Abingworth LLP (15.61%), J. Goldman & Co LP (0.47%), Renaissance Technologies LLC (0.29%), Banco Bilbao Vizcaya Argentaria S.A. (0.11%), Shikiar Asset Management Inc. (0.08%) and Lindbrook Capital LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Institutional Ownership Trends for Soleno Therapeutics.

SLNO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Bioasia Mangement Llc, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Insider Buying and Selling for Soleno Therapeutics.

SLNO stock was purchased by a variety of institutional investors in the last quarter, including Abingworth LLP, J. Goldman & Co LP, Banco Bilbao Vizcaya Argentaria S.A., Lindbrook Capital LLC and Shikiar Asset Management Inc.. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SLNO stock can currently be purchased for approximately $3.37.

Soleno Therapeutics has a market capitalization of $150.50 million. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.

The official website for Soleno Therapeutics is http://www.soleno.life/.

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]